Lobbying Filing Details

Total Spending

$430,000

Activities

3

Lobbyists

3

Gov't Entities

6

Filing Information
Filing UUID:
d7eb07f6-8f0c-4d6f-9fce-1a367d6a69da
Type:
Q2 - 2nd Quarter - Report
Period:
2017 - 2nd Quarter (Apr 1 - June 30)
Date Posted:
July 20, 2017 at 6:34 PM
Income:
$0
Expenses:
$430,000
Expense Method:
Method A - Reporting amounts using LDA definitions only
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Joseph Devaney
Registrant
ASTELLAS PHARMA US, INC.

Pharmaceuticals

Northbrook, Illinois
Client
ASTELLAS PHARMA US, INC.
Illinois, United States of America
Lobbying Activities (3)
Activity 1
Health Issues

Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act of 2017 (H.R.1409); Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to the Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to importation (no specific bills).

Foreign Entity Issues: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

Lobbyists (3)
  • MRS. MARY LACEY REUTHER
  • MS. MELISSA WIER BANASHAK
  • SARAH CHRISTINE D'ORSIE
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 2
Medicare/Medicaid

Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues.
S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB)
S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB
H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB
H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal

Foreign Entity Issues: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

Lobbyists (3)
  • MRS. MARY LACEY REUTHER
  • MS. MELISSA WIER BANASHAK
  • SARAH CHRISTINE D'ORSIE
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 3
Taxation/Internal Revenue Code

Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment; comprehensive tax reform.

Foreign Entity Issues: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

Lobbyists (3)
  • MRS. MARY LACEY REUTHER
  • MS. MELISSA WIER BANASHAK
  • SARAH CHRISTINE D'ORSIE
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES

Source: LDA.gov, data retrieved November 9, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.